Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P48546
UPID:
GIPR_HUMAN
Alternative names:
Glucose-dependent insulinotropic polypeptide receptor
Alternative UPACC:
P48546; B7WP14; B7ZKQ0; Q14401; Q16400; Q52M04; Q9UPI1
Background:
The Gastric inhibitory polypeptide receptor, also known as the Glucose-dependent insulinotropic polypeptide receptor, plays a pivotal role in metabolic processes. Identified by its unique identifier P48546, this receptor is integral in mediating the effects of GIP through G proteins that activate adenylyl cyclase. Its involvement in the regulation of insulin secretion in response to glucose makes it a critical component in maintaining glucose homeostasis.
Therapeutic significance:
Understanding the role of the Gastric inhibitory polypeptide receptor could open doors to potential therapeutic strategies. Its central function in glucose metabolism and insulin regulation positions it as a promising target for the development of treatments for metabolic disorders.